Вы находитесь на странице: 1из 25

J.P.

MORGAN CONFERENCE
JANUARY 8, 2018

BRENT SAUNDERS
CHAIRMAN AND CEO
ALLERGAN Cautionary Statements
forward looking statements
This communication includes statements that refer to estimated or anticipated future events and are forward looking statements. We have based our forward looking statements on management’s beliefs and assumptions based on
information available to our management at the time these statements are made. Such forward looking statements reflect our current perspective of our business, future performance, existing trends and information as of the date of
this filing. These include, but are not limited to, our beliefs about future revenue and expense levels and growth rates, prospects related to our strategic initiatives and business strategies, including the integration of, and synergies
associated with, strategic acquisitions, express or implied assumptions about government regulatory action or inaction, anticipated product approvals and launches, business initiatives and product development activities, assessments
related to clinical trial results, product performance and competitive environment, and anticipated financial performance. Without limiting the generality of the foregoing, words such as “may,” “will,” “expect,” “believe,” “anticipate,”
“plan,” “intend,” “could,” “would,” “should,” “estimate,” “continue,” or “pursue,” or the negative or other variations thereof or comparable terminology, are intended to identify forward looking statements. The statements are not
guarantees of future performance and involve certain risks, uncertainties and assumptions that are difficult to predict. We caution the reader that these statements are based on certain assumptions, risks and uncertainties, many of
which are beyond our control. In addition, certain important factors may affect our actual operating results and could cause such results to differ materially from those expressed or implied by forward looking statements. These
factors include, among others the inherent uncertainty associated with financial projections; the anticipated size of the markets and continued demand for Allergan’s existing products; Allergan’s ability to successfully develop and
commercialize new products; Allergan’s ability to conform to regulatory standards and receive requisite regulatory approvals; availability of raw materials and other key ingredients; uncertainty and costs of legal actions and
government investigations; fluctuations in Allergan’s operating results and financial condition, particularly given our manufacturing and sales of branded products; the impact of uncertainty around of timing of generic entry related to
key products, including Restasis ®, on our financial results; risks associated with acquisitions, mergers and joint ventures, such as difficulties integrating businesses, uncertainty associated with financial projections, projected cost
reductions, projected synergies, restructurings, increased costs, and adverse tax consequences; expectations regarding contingent payments, including regarding litigation and related liabilities, purchase price adjustment or
transaction consideration payments; the results of the ongoing business following the completion of the divestiture of Allergan’s generics business to Teva; the adverse impact of substantial debt and other financial obligations on the
ability to fulfill and/or refinance debt obligations; risks associated with relationships with employees, vendors or key customers as a result of acquisitions of businesses, technologies or products; our compliance with federal and state
healthcare laws, including laws related to fraud, abuse, privacy security and others; generic product competition with our branded products; uncertainty associated with the development of commercially successful branded
pharmaceutical products; costs and efforts to defend or enforce technology rights, patents or other intellectual property; expiration of patents on our branded products and the potential for increased competition from generic
manufacturers; competition between branded and generic products; Allergan’s ability to obtain and afford third-party licenses and proprietary technology we need; Allergan’s potential infringement of others’ proprietary rights; our
dependency on third-party service providers and third-party manufacturers and suppliers that in some cases may be the only source of finished products or raw materials that we need; Allergan’s competition with certain of our
significant customers; the impact of our returns, allowance and chargeback policies on our future revenue; successful compliance with governmental regulations applicable to Allergan’s and Allergan’s respective third party providers’
facilities, products and/or businesses; the difficulty of predicting the timing or outcome of product development efforts and regulatory agency approvals or actions, if any; Allergan’s vulnerability to and ability to defend against product
liability claims and obtain sufficient or any product liability insurance; Allergan’s ability to retain qualified employees and key personnel; the effect of intangible assets and resulting impairment testing and impairment charges on our
financial condition; Allergan’s ability to obtain additional debt or raise additional equity on terms that are favorable to Allergan; difficulties or delays in manufacturing; our ability to manage environmental liabilities; global economic
conditions; Allergan’s ability to continue foreign operations in countries that have deteriorating political or diplomatic relationships with the United States; Allergan’s ability to continue to maintain global operations and the exposure to
the risks and challenges associated with conducting business internationally; risks associated with tax liabilities, or changes in U.S. federal or international tax laws to which we are subject, including the risk that the Internal Revenue
Service disagrees that Allergan is a foreign corporation for U.S. federal tax purposes; risks of fluctuations in foreign currency exchange rates; risks associated with cyber-security and vulnerability of our information and employee,
customer and business information that Allergan stores digitally; Allergan’s ability to maintain internal control over financial reporting; changes in the laws and regulations, affecting among other things, availability, pricing and
reimbursement of pharmaceutical products; the highly competitive nature of the pharmaceutical industry; Allergan’s ability to successfully navigate consolidation of our distribution network and concentration of our customer base; the
difficulty of predicting the timing or outcome of pending or future litigation or government investigations; developments regarding products once they have reached the market; risks related to Allergan’s incorporation in Ireland, such
as changes in Irish law and such other risks and other uncertainties detailed in Allergan’s periodic public filings with the Securities and Exchange Commission, including but not limited to Allergan’s Annual Report on Form 10-K for the
year ended December 31, 2016 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2017, and from time to time in Allergan’s other investor communications. Except as expressly required by law, Allergan
disclaims any intent or obligation to update or revise these forward-looking statements.

Non‐GAAP Financial Measures


This document contains non‐GAAP financial measures. The Appendix hereto presents reconciliations of certain non‐GAAP financial measures to the most directly comparable GAAP measures. The non‐GAAP measures include non-GAAP
performance net income, non-GAAP performance net income per share, adjusted EBITDA, non-GAAP operating income and other non-GAAP financial statement line items.

The Company believes that its non-GAAP measures provide useful information to investors because these are the financial measures used by our management team to evaluate our operating performance, make day to day operating
decisions, prepare internal forecasts, communicate external forward looking guidance to investors, compensate management and allocate the Company’s resources. We believe this presentation also increases comparability of period
to period results.

The Company’s determination of significant charges or credits may not be comparable to similar measures used by other companies and may vary from period to period. The Company uses both GAAP financial measures and the
disclosed non-GAAP adjusted financial measures internally. These non-GAAP adjusted financial measures are in addition to, not a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP.

2
Unlocking Value in 2018 and Beyond

1 Our Priorities and Strategy

2 Expanding Our Leadership in Key Therapeutic Areas

3 Open Science and Development

4 Financial Outlook

3
Strategic Objectives to Drive Shareholder Return

Deliver Durable Underlying Advancing the Pipeline


Revenue Growth Beyond 6 Stars
Extend category leadership in key TAs Growth Pipeline Key catalysts on 6 Stars
Drive double digit international growth File Vraylar in bipolar depression
~5% CAGR 2017–2022 Bimatoprost SR Phase 3
Extending the late stage pipeline
EXECUTION
Commitment to Strong Margins Capital Deployment
Right-size organization for Continued debt paydown
long-term success Margins Capital Target Gross Debt/EBITDA ~3x*
Focus investments in key commercial Allocation
Share repurchase
and R&D growth drivers
Annual dividend increase
Future margin expansion through pipeline
Disciplined investment for long-term growth

* Expect 2018 gross debt/EBITDA exit at ~3.3x

4
Our Balanced Portfolio Provides Durable Growth
Driven by Volume Demand
2017 YTD* Rev Performance Drivers Reimbursed vs Cash Pay & Botox Tx

33%
33% 42%
44%
YTD
2017 2022
67% 56%
67% 58%
Cash Pay Reimbursed

US vs International
79%
21% 21% 29% 29%
YTD
2017 2022
71%
* As of Sept-30-17. Refer to Table 1 in the appendix
1. Includes new product launches. 2 Includes established brands, all other product revenues and other
79%
revenues. Includes revenues reclassified to Discontinued Operations related to the portion of Allergan product 71%
revenues sold by our former Anda Distribution Business. 3 Includes brands with patent expiration and/or risk International US
of generic competition 2018-2020

5
Extending Category Leadership in Key TAs

Promoted
Brands
Driving
Growth

Drive market Strengthen Expand into Shift paradigm Leverage Maximize value
expansion leadership in CNS new areas treatment for commercial leadership and profitability
glaucoma & retina for future launches
TA Use technology to drive Take Vraylar to $1B+ by Build on IBS leadership Shift glaucoma to Drive strong, profitable Focused, contained
Strategy consumer demand expanding indications with Linzess and Viberzi drop-less therapy growth with Lo Loestrin hospital based sales
force
Expand into skin Transform migraine Enter gastroparesis, Create a flagship Prepare for
quality/tightening; hair and depression Crohn’s and NASH with Abicipar in retina Esmya launch Launch new HAP/VAP
growth indication for Avycaz

Botox CGRPs Brazikumab Abicipar Ceftazidime /Avibactam


(Masseter/Platysma) Esmya
Cariprazine (HAP/VAP Bacterial
New fillers CVC/FXR Bimataprost SR Pneumonia)
Key (Volite/Voluma+) Rapastinel
Pipeline Artia (breast Relamorelin Pilo/Oxy Dalbavancin
reconstruction) AGN-242647
(Parkinson’s) (endocarditis)
Revolve (adipose
tissue) AGN-241751
(MDD)
CoolSculpting

6
Leading in Medical Aesthetics
Pioneered Facial Injectables & Plastics

CoolSculpting

Revolve Artia
(Adipose tissue) (Breast reconstruction)

New fillers Botox


(Volite/Voluma+) (Platysma/Masseter)

Past Present Future


7
– An Iconic Brand
A Gateway to Leadership in Medical Aesthetics

>3.5M Members
~80% Unaided of Brilliant
brand awareness Distinctions 3 Decades
(80x competitor) of Market
5x # Medical Experience
Aesthetics
Sales Reps vs Differentiated
2nd largest and Durable 3,200 Articles
competitor Best-in-Class
Physician
Franchise published in
Training 12 Peer-reviewed
Journals
Indications
3 Cx / 9 Tx

Practice Building
New Customers New Therapeutic Categories
Opportunities
* Sources: Brand awareness: Direct-to-Consumer Tracker, NTX Quarterly Reporting Q2, 2015 Through Q2, 2017. Sales Reps vs. competitor: Competitive intelligence/market surveillance

8
Strengthening Leadership in CNS

Rapastinel
(MDD)

CGRPs Cariprazine
(Migraine) (Bipolar Dep.)

AGN242647 AGN241751
(Parkinson’s) (MDD)

Past Present Future


9
– Building Into a Blockbuster
Peak Sales Outlook

Existing Indications Bipolar Negative Adjunctive Major


(US Sales, $B)

+Schiz. Depression (BPD) Symptoms Depressive Disorder (aMDD) 2030


Maintenance LOE

$0.5B+ $0.5B+ $0.3B+ $1B+ $2–3B Peak

Bipolar Bipolar Adj. Negative Vraylar could be the only approved


Schizophrenia
Mania Depression MDD Symptoms treatment on the market with all 4
indications plus negative symptoms
✓ ✓ Phase 3 Phase 3 Phase 3
Bipolar depression could launch in
✓ ✓ ✓ ✓
2019, after Latuda LOE, allowing 100%
✓ ✓ ✓ share of voice in BPD
✓ ✓ Positive studies already complete for
✓ ✓ both Adjunctive MDD and Negative
Symptoms
✓ ✓

10
Addressing Most Significant Needs in GI

Brazikumab
(Crohn’s/UC)

CVC/FXR Relamorelin
(NASH) (Gastroparesis)

Past Present Future


11
Expanding Our GI Leadership to New Areas
Enter into Areas of Unmet Need

Relamorelin Brazikumab Cenicriviroc and FXR


Diabetic Gastroparesis Crohn’s Disease / UC NASH

First potential pro-kinetic treatment Novel IL-23 antibody Phase 2 data strongly supports
option in over 30 years anti-fibrotic activity for CVC

High unmet medical need with >2mm Targeted approach to development Optimizing long-term development
patients with moderate–severe for combination approaches
gastroparesis in US
>1.5mm US patients with Crohn’s and 6-10mm US patients with
Ulcerative Colitis (UC) advanced fibrosis

Sources:
Crohn’s and Colitis Foundation, Truven Health Analytics
International Foundation for Functional Gastrointestinal Disorders, EvaluatePharma
Angulo et al. Hepatology 1999; Matteoni et al. Gastroenterology 1999. HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis

12
Shifting the Paradigm in Eye Care Treatment
Abicipar
(AMD, DME)

Pilo/Oxy Bimatoprost SR
(Presbyopia) (Glaucoma)

Past Present Future


13
Sustained International Double Digit Growth
DRIVING PROFITABLE GROWTH FOCUSED INVESTMENT AND EXECUTION
Past Present Outlook
5 Key Growth Drivers
Driving ~80% of growth YTD**
Revenue
Growth

7% 10% Double-
2016 2017 digit Therapeutic
PF YoY* YTD**
Model

Direct- Market Russia


Distributor Great Britain
selling building Canada
Germany
France
China

12
Spain Turkey
Contribution

Italy Saudi Arabia

Must-win
Margin

54% 54% +60% markets Brazil


2016 YTD 2017 Accounting for Australia
~65% of growth
YTD
* Includes 12 months of AGN Inc in 2015.
** Excludes 2017 contribution from Lifecell and Zeltiq. YTD as of Sep 30, 2017. Figures are non-GAAP

14
Open Science and Development Model
What Distinguishes Allergan Track Record of Approved Drugs
Number of NME/BLA approvals 2009–2017 YTD1

17 16

16
>200%
industry
15
average

15

13

11

10

Source: Deloitte. A new future for R&D?: Measuring the return from pharmaceutical innovation 2017. 1. Includes new fixed-dose combinations and co-developments
Report on the Internet 2017. Data based on 2015 to 2017 average return on investment SOURCE: Mckinsey analysis based on Evaluate; FDA; Press search
Available from: deloitte.co.uk/measuringRnDreturns

15
Advancing the Pipeline Beyond 6 Stars
Estimated timelines 2017 2018 2019 2020
ESMYA FDA approval
Uterine fibroids and launch
Ubrogepant Ph. III recruitment Ph. III topline Launch
Acute migraine complete results
Atogepant Ph. IIb topline
Prophylaxis migraine results
Cariprazine Positive Ph. III Launch
Bipolar Depression topline
Rapastinel Ph. III on track Ph. III short-term
Depression topline results
Abicipar Ph. III topline Launch
AMD results
Abicipar Ph. III initiation
DME

Bimatoprost SR Ph. III enrollment Launch


Glaucoma completion
Pilo/Oxy Ph. IIb enrollment
Presbyopia completion Ph. III initiation
CVC Ph. III initiated
NASH

Relamorelin Ph. III initiated Ph. III topline


Gastroparesis results
Brazikumab Ongoing Ph. II Ph. III initiation
Crohn’s
Brazikumab Ph. II initiation
UC
RORyT Ongoing Ph. II Ph. III initiation
Psoriasis

Botox Ongoing Ph. IIb/III


Platysma/Masseter

Potential Peak Sales greater than Allergan sales today 16


Managing Through LOEs and Positioning Allergan
for Long-Term Success

Key Assumptions Updated Framework

• Restasis: Gx entry not expected prior to Q2 2018 • 2018 Net Revenues $15,000M–15,300M

• Estrace (Gx already in market); Namenda XR • Potential FY 2018 non-GAAP performance


(early Q1’18); Delzicol (early Q2’18); Aczone net income per share*:
(highly generic mkt)

• Ongoing cost reductions of $300M–$400M from ≥$15.25


FY 2017 non-GAAP operating expenses

• Expect non-GAAP performance net income


• Expect non-GAAP tax rate in 2018 up to ~15% per share growth in FY 2019 versus FY 2017

* Refer to Table 2 in Appendix for GAAP to non-GAAP reconciliation

17
2018 Operating Expense Reduction
> Includes cost reductions in certain field forces and promotional > Reducing internal basic research investments, de-
spending in brands facing LOE exposure and generic prioritizing lower potential programs.
competition.
> Includes optimization of key mid-late stage
> Includes increasing investments in Medical Aesthetics, other development programs.
key brands, and International.

~$6.15B*

~$5.75B–$5.85B
~$250M–$300M
~$50M–$100M

~1,000 headcount reduction

FYE2017 Non-GAAP SG&A Cost R&D Cost FYE2018 Non-GAAP


Operating Expenses Reductions Reductions Operating Expenses
* Mid-point of FY 2017 guidance. Refer to table 3 in Appendix for GAAP to non-GAAP reconciliation
The Company expects to incur related restructuring costs of approximately $125 million, primarily due to severance, the majority of which will be recorded in the fourth quarter ended December 31,
2017. These amounts do not include additional charges related to potential building closures, contract terminations, and other items.

18
Revenue Growth Outlook

~5% CAGR

pipeline Outlook:
Outlook:
Declining as per
Flat to single
LOE exposure
digit decline
Outlook:
High single digit
organic growth

2017 Promoted Non-promoted Brands Facing 2022


Brands Brands Near Term LOE Risk*

2017
% Revenues
70% 10% 20%

2022
% Revenues
90% 5% 5%

* Includ in 2022: Bystolic; Alphagan/Combigan; Viibryd; Saphris; Teflaro. Included in 2017: Restasis; Estrace; Aczone; Delzicol; Canasa; Namenda XR; Rapaflo
Chart not at scale

19
Why I Am Optimistic About Our Future

1 Durable growth underlying business

2 Strengthening & extending therapeutic leadership

3 Deep pipeline with high potential

4 Right-sized organization for future success

5 Strong cash flow & balance sheet outlook

20
APPENDIX

21
Committed to Investment Grade Credit
and Disciplined Capital Allocation
42.6 Gross Debt reduced by
39.6 $12.2B since March 31, 2016

$3.75B senior note


maturities to be paid
32.8 32.8
31.8 in Q1’18
30.3 30.4

Q1'16 Q2'16 Q3'16 Q4'16 Q1'17 Q2'17 Q3'17 Q4'17 Q1'18

Gross Debt/Adj EDITDA 4.4x 4.2x 4.3x 4.3x 4.2x 4.0x 3.9x ~3.3x

Target
Long Term Leverage
Target Ratio
Gross Debt to~3x
EBITDA ~3x

22
Table 1: 2017 YTD Revenue Performance Drivers by product
The following presents Allergan plc's revenue performance by product for the nine months ended September 30, 2017 and 2016 (Unaudited; $ in millions):
Table 14

Nine Months Ended September 30, 2017 Nine Months Ended September 30, 2016 Movement

US Specialized US General US Specialized US General Total Change


Therapeutics Medicine International Corporate Total Therapeutics Medicine International Corporate Total Total Change Percentage

Botox® $ 1,642.0 $ - $ 662.6 $ - $ 2,304.6 $ 1,454.0 $ - $ 592.9 $ - $ 2,046.9 $ 257.7 12.6%


Juvederm Collection 361.6 - 386.0 - 747.6 325.3 - 304.2 - 629.5 118.1 18.8%
Linzess®/Constella® - 506.3 16.1 - 522.4 - 452.0 12.7 - 464.7 57.7 12.4%
® ®
Lumigan /Ganfort 236.6 - 271.8 - 508.4 240.4 - 269.2 - 509.6 (1.2) -0.2%
® ®
Bystolic /Byvalson - 454.7 1.6 - 456.3 - 479.0 1.3 - 480.3 (24.0) -5.0%
® ®
Alphagan /Combigan 275.5 - 128.4 - 403.9 274.3 - 127.3 - 401.6 2.3 0.6%
Eye Drops 152.2 - 207.2 - 359.4 140.1 - 206.9 - 347.0 12.4 3.6%
Lo Loestrin® - 332.8 - - 332.8 - 296.0 - - 296.0 36.8 12.4%
Breast Implants 173.6 - 116.8 - 290.4 149.2 - 112.5 - 261.7 28.7 11.0%
Viibryd®/Fetzima® - 244.2 2.1 - 246.3 - 252.6 0.1 - 252.7 (6.4) -2.5%
Alloderm 223.3 5.0 - 228.3 - - 228.3 n.a.
Vraylar™ - 200.1 - - 200.1 - 51.1 - - 51.1 149.0 n.m.
Coolsculpting Consumables 98.2 26.3 - 124.5 - - 124.5 n.a.
Ozurdex ® 72.0 - 152.5 - 224.5 61.8 - 130.2 - 192.0 32.5 16.9%
® ®
Carafate /Sulcrate - 176.6 2.1 - 178.7 - 167.7 1.7 - 169.4 9.3 5.5%
®
Zenpep - 153.8 - - 153.8 - 145.1 - - 145.1 8.7 6.0%
Coolsculpting Systems & Add On Applicators 64.1 20.4 - 84.5 - - 84.5 n.a.
Viberzi® - 113.7 0.3 - 114.0 - 55.3 - - 55.3 58.7 106.1%
®
Namzaric - 94.0 - - 94.0 - 38.0 - - 38.0 56.0 147.4%
®
Teflaro - 92.7 - - 92.7 - 101.9 - - 101.9 (9.2) -9.0%
®
Dalvance - 40.9 1.2 - 42.1 - 26.7 - - 26.7 15.4 57.7%
®
Avycaz - 42.7 - - 42.7 - 26.9 - - 26.9 15.8 58.7%
® ®
Kybella /Belkyra 37.4 - 5.1 - 42.5 38.2 - 1.6 - 39.8 2.7 6.8%
Other Regenerative medicines 81.7 - 5.7 - 87.4 - - - - - 87.4 n.a.
Other Promoted and New Launch Products 10.8 - 12.0 - 22.8 - 3.7 - 3.7 19.1 n.m.
Total Promoted Brands and Brands With Ongoing
Exclusivity 3,429.0 2,452.5 2,023.2 - 7,904.7 2,683.3 2,092.3 1,764.3 - 6,539.9 1,364.8 20.9%

Restasis® 1,012.0 - 46.7 - 1,058.7 1,026.4 - 49.7 - 1,076.1 (17.4) -1.6%


®
Namenda XR - 355.0 - - 355.0 - 486.5 - - 486.5 (131.5) -27.0%
®
Estrace Cream - 265.1 - - 265.1 - 276.4 - - 276.4 (11.3) -4.1%
® ®
Asacol /Delzicol - 152.7 36.8 - 189.5 - 297.9 40.5 - 338.4 (148.9) -44.0%
®
Aczone 128.3 - 0.3 - 128.6 156.1 - - - 156.1 (27.5) -17.6%
® ®
Canasa /Salofalk - 115.7 13.3 - 129.0 - 135.0 13.0 - 148.0 (19.0) -12.8%
®
Rapaflo 79.9 - 5.5 - 85.4 87.6 - 4.2 - 91.8 (6.4) -7.0%
®
Minastrin 24 - 56.1 - - 56.1 - 247.5 1.4 - 248.9 (192.8) -77.5%
®
Namenda IR - 0.1 - - 0.1 - 12.8 - - 12.8 (12.7) -99.2%
Total Brands Facing LOE / Risk 1,220.2 944.7 102.6 - 2,267.5 1,270.1 1,456.1 108.8 - 2,835.0 (567.5) -20.0%

Saphris® - 117.5 - - 117.5 - 123.6 - - 123.6 (6.1) -4.9%


®
Tazorac 51.3 - 0.5 - 51.8 68.0 - 0.6 - 68.6 (16.8) -24.5%
®
SkinMedica 72.1 - 1.4 - 73.5 81.5 - - - 81.5 (8.0) -9.8%
®
Latisse 40.5 - 6.2 - 46.7 54.7 - 6.2 - 60.9 (14.2) -23.3%
®
Liletta - 23.1 - - 23.1 - 15.0 - - 15.0 8.1 54.0%
Armour Thyroid - 117.8 - - 117.8 - 121.8 - - 121.8 (4.0) -3.3%
Savella® - 74.3 - - 74.3 - 74.1 - - 74.1 0.2 0.3%
Lexapro® - 39.4 - - 39.4 - 50.8 - - 50.8 (11.4) -22.4%
Enablex® - 2.8 - - 2.8 - 14.7 - - 14.7 (11.9) -81.0%
Other Products Revenues 108.7 498.8 269.7 18.3 895.5 83.2 442.5 248.2 26.5 800.4 95.1 11.9%
Less product sold through our former Anda Distribution
business n.a. n.a. n.a. - - n.a. n.a. n.a. (80.0) (80.0) 80.0 -100.0%

23
Total all other 272.6 873.7 277.8 18.3 1,442.4 287.4 842.5 255.0 (53.5) 1,331.4 111.0 8.3%

Total Net Revenues $ 4,921.8 $ 4,270.9 $ 2,403.6 $ 18.3 11,614.6 $ 4,240.8 $ 4,390.9 $ 2,128.1 $ (53.5) 10,706.3 $ 908.3 8.5%
Table 2
Reconciliation of illustrative GAAP loss from continuing operations to the illustrative non-GAAP performance net income
attributable to shareholders for the year ending December 31, 2018 based on the potential scenario of Non-GAAP
Performance Net Income Per Share of $15.25.
2018 at Non-GAAP
Performance Net
Income Per Share of
in millions except per share amounts $15.25
GAAP (loss) from continuing operations attributable to shareholders $ (288.8)
Adjusted for:
Amortization 6,450.0
Acquisition, integration and licensing charges 450.0
Accretion and fair-value adjustments to contingent consideration (5.0)
Impairment/asset sales and related costs 200.0
Non-recurring (gain) / losses -
Global Supply Chain Initiatives -
Legal settlements -
Income taxes on items above and other income tax adjustments (1,446.2)

Non-GAAP performance net income attributable to shareholders 5,360.0

Diluted earnings per share


Diluted (loss) per share from continuing operations attributable to shareholders- GAAP $ (0.84)

Non-GAAP performance diluted net income per share attributable to shareholders $ 15.25

Basic weighted average ordinary shares outstanding 345.0


Effect of dilutive securities:
Dilutive shares 6.5
Diluted weighted average ordinary shares outstanding 351.5

24
Table 3
Select Income Statement Guidance Ranges

Full Year 2018 Select Guidance GAAP NON-GAAP

Total Net Revenues ~$15.0 - $15.3 billion ~$15.0 - $15.3 billion

SG&A Expense ~$4.35 - $4.40 billion ~$4.25 - $4.30 billion

R&D Expense ~$1.85 - $1.90 billion ~$1.5 - $1.55 billion

25